Hudson Bay Capital Management LP Invests $563,000 in Henry Schein, Inc. $HSIC

Hudson Bay Capital Management LP purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 8,489 shares of the company’s stock, valued at approximately $563,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HSIC. Ameriprise Financial Inc. raised its position in Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the last quarter. Norges Bank acquired a new position in Henry Schein in the second quarter worth $89,476,000. M.D. Sass LLC bought a new stake in shares of Henry Schein during the second quarter worth $79,201,000. Schroder Investment Management Group increased its stake in shares of Henry Schein by 149.3% in the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on HSIC shares. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Wells Fargo & Company raised their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their target price on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Morgan Stanley upped their target price on shares of Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 25th. Finally, Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $74.46 on Tuesday. The firm has a fifty day moving average of $77.69 and a two-hundred day moving average of $73.10. The stock has a market capitalization of $8.54 billion, a price-to-earnings ratio of 22.77, a PEG ratio of 2.14 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period last year, the company earned $1.19 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Stanley M. Bergman sold 43,812 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares in the company, valued at approximately $31,207,021.93. This trade represents a 10.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the transaction, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 105,911 shares of company stock valued at $8,574,982. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.